ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,275.38
0.54%
Dow Jones
38,686.32
1.51%
Gold vs US Dollar
2,327.355
0.00%
Brent Oil
81.295
0.00%
Bitcoin
67,754.83
0.04%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE
  6. Merck and Co Inc (MRK)

  7. Merck and Co Inc (MRK) News

Merck (MRK)

Merck and Co Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:MRK
DateTimeSourceHeadlineSymbolCompany
30/05/202421:39Edgar (US Regulatory)Form CERT - Certification by an exchange approving securities for listingNYSE:MRKMerck and Co Inc
30/05/202421:28Edgar (US Regulatory)Form 8-A12B - Registration of securities [Section 12(b)]NYSE:MRKMerck and Co Inc
30/05/202421:14Edgar (US Regulatory)Form 8-K - Current reportNYSE:MRKMerck and Co Inc
29/05/202414:10IH Market NewsRising Treasury Yields May Weigh On Wall StreetNYSE:MRKMerck and Co Inc
29/05/202412:34IH Market NewsRobinhood Shares Surge 3.3% on Stock Buyback Announcement; Anglo Declines BHP Deadline Extension, and More NewsNYSE:MRKMerck and Co Inc
29/05/202412:15Business WireFDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural MesotheliomaNYSE:MRKMerck and Co Inc
29/05/202411:45Business WireMerck to Acquire EyeBioNYSE:MRKMerck and Co Inc
28/05/202421:44IH Market NewsNasdaq Climbs To Another Record Closing High But Dow Sees Further DownsideNYSE:MRKMerck and Co Inc
28/05/202421:31Edgar (US Regulatory)Form SD - Specialized disclosure reportNYSE:MRKMerck and Co Inc
28/05/202420:12Business WireMerck Announces Third-Quarter 2024 DividendNYSE:MRKMerck and Co Inc
28/05/202411:45Business WireMerck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival (OS) Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)NYSE:MRKMerck and Co Inc
20/05/202411:28Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NYSE:MRKMerck and Co Inc
16/05/202421:15Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNYSE:MRKMerck and Co Inc
15/05/202416:31Edgar (US Regulatory)Form POSASR - Post-effective Amendment to an automatic shelf registration statementNYSE:MRKMerck and Co Inc
15/05/202411:45Business WireMerck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse PipelineNYSE:MRKMerck and Co Inc
13/05/202411:45Business WireMerck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk MelanomaNYSE:MRKMerck and Co Inc
09/05/202412:05PR Newswire (Canada)Santé Canada approuve KEYTRUDA® pour le traitement, en association avec une chimiothérapie à base de gemcitabine, des adultes atteints d'un carcinome des voies biliaires non résécable localement avancé ou métastatiqueNYSE:MRKMerck and Co Inc
09/05/202412:05PR Newswire (Canada)Health Canada Approves KEYTRUDA® for adult patients with locally advanced unresectable or metastatic biliary tract carcinoma, in combination with gemcitabine-based chemotherapyNYSE:MRKMerck and Co Inc
09/05/202411:45Business WireMerck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative IntentNYSE:MRKMerck and Co Inc
08/05/202411:45Business WireMerck to Participate in the Bank of America Securities 2024 Healthcare ConferenceNYSE:MRKMerck and Co Inc
06/05/202421:29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:MRKMerck and Co Inc
06/05/202421:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:MRKMerck and Co Inc
06/05/202421:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:MRKMerck and Co Inc
06/05/202421:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:MRKMerck and Co Inc
06/05/202421:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:MRKMerck and Co Inc
01/05/202412:15Business WireMerck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaNYSE:MRKMerck and Co Inc
29/04/202414:00Business WireMerck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for AdultsNYSE:MRKMerck and Co Inc
25/04/202421:40IH Market NewsU.S. Stocks Climb Well Off Worst Levels But Close Mostly LowerNYSE:MRKMerck and Co Inc
25/04/202414:09IH Market NewsFutures Pointing To Sharply Lower Open On Wall StreetNYSE:MRKMerck and Co Inc
25/04/202412:52IH Market NewsSouthwest Shares Tumble 9.6% Post $231 Million 1Q Loss, AstraZeneca Surges on 19% Annual Increase, and More on EarningsNYSE:MRKMerck and Co Inc
 Showing the most relevant articles for your search:NYSE:MRK

Your Recent History

BOV
PORT3F
Wilson Sons Holdings Bra... ON
NYSE
SWK
Stanley Black and Decker
NYSE
DRI
Darden Restaurants
ASX
KFM
Kingfisher Mining
USOTC
VYGVF
Voyager Digital (PK)
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved